These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19065486)

  • 61. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.
    Heitmiller RF; Redmond M; Hamilton SR
    Ann Surg; 1996 Jul; 224(1):66-71. PubMed ID: 8678620
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett's dysplasia and mucosal carcinoma.
    Shah AK; Wolfsen HC; Hemminger LL; Shah AA; DeVault KR
    Dis Esophagus; 2006; 19(5):335-9. PubMed ID: 16984528
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.
    Mino-Kenudson M; Ban S; Ohana M; Puricelli W; Deshpande V; Shimizu M; Nishioka NS; Lauwers GY
    Am J Surg Pathol; 2007 Mar; 31(3):403-9. PubMed ID: 17325482
    [TBL] [Abstract][Full Text] [Related]  

  • 65. EUS in the management of the patient with dysplasia in Barrett's esophagus.
    Savoy AD; Wallace MB
    J Clin Gastroenterol; 2005 Apr; 39(4):263-7. PubMed ID: 15758616
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Photodynamic therapy and endoscopic mucosal resection for Barrett's dysplasia and early esophageal adenocarcinoma.
    Wolfsen HC; Hemminger LL; Raimondo M; Woodward TA
    South Med J; 2004 Sep; 97(9):827-30. PubMed ID: 15455964
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett's esophagus and adenocarcinoma of the gastrica cardia.
    Conio M; Cameron AJ
    Gastrointest Endosc; 2001 Dec; 54(6):799-801. PubMed ID: 11762326
    [No Abstract]   [Full Text] [Related]  

  • 68. Current state of endoscopic therapies in Barrett's esophagus and esophageal cancer.
    Hudson M; Lin CL; Habr F
    Hosp Pract (1995); 2011 Feb; 39(1):170-80. PubMed ID: 21441773
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem.
    Rusch VW; Levine DS; Haggitt R; Reid BJ
    Cancer; 1994 Aug; 74(4):1225-9. PubMed ID: 8055442
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Photodynamic therapy for esophageal diseases: a clinical update.
    Prosst RL; Wolfsen HC; Gahlen J
    Endoscopy; 2003 Dec; 35(12):1059-68. PubMed ID: 14648421
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Screening and surveillance for complications related to gastroesophageal reflux disease.
    Spechler SJ
    Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
    Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
    Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit.
    Moss A; Bourke MJ; Hourigan LF; Gupta S; Williams SJ; Tran K; Swan MP; Hopper AD; Kwan V; Bailey AA
    Am J Gastroenterol; 2010 Jun; 105(6):1276-83. PubMed ID: 20179694
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD; Buckles D; Al-Kasspooles M
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
    Etienne J; Dorme N; Bourg-Heckly G; Raimbert P; Fékété F
    Bull Acad Natl Med; 2000; 184(8):1731-44; discussion 1744-7. PubMed ID: 11471391
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Barrett esophagus with severe dysplasia in argon beam therapy].
    Maass S; Martin WR; Spiethoff A; Riemann JF
    Z Gastroenterol; 1998 Apr; 36(4):301-6. PubMed ID: 9612928
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia.
    Falk GW; Rice TW; Goldblum JR; Richter JE
    Gastrointest Endosc; 1999 Feb; 49(2):170-6. PubMed ID: 9925694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.